Madrigal Pharmaceuticals Inc (MDGL)
331.32
0.00 (0.00%)
USD |
NASDAQ |
Nov 05, 09:31
Madrigal Pharmaceuticals Gross Profit Margin (Quarterly): 96.54% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 96.54% |
| June 30, 2024 | 95.66% |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 |
| Date | Value |
|---|---|
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
95.66%
Minimum
Jun 2024
96.54%
Maximum
Sep 2024
96.10%
Average
96.10%
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 92.47% |
| Sarepta Therapeutics Inc | 87.73% |
| ADMA Biologics Inc | 53.60% |
| Intra-Cellular Therapies Inc | 91.26% |
| Entrada Therapeutics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -89.04% |
| Return on Assets | -62.73% |
| Return on Invested Capital | -74.25% |
| Profit Margin (Quarterly) | -172.0% |
| Operating Margin (Quarterly) | -187.1% |
| Return on Net Operating Assets | -2.12K% |